VTGN - VistaGen Therapeutics GAAP EPS of -$0.25 misses by $0.03 revenue of $1.11M misses by $0.21M

VistaGen Therapeutics press release (NASDAQ:VTGN): FY GAAP EPS of -$0.25 misses by $0.03. Revenue of $1.11M (+1.8% Y/Y) misses by $0.21M. At March 31, 2022, the Company had cash and cash equivalents of approximately $68.1 million. Completed last patient out milestone for PALISADE-1 Phase 3 clinical trial of PH94B in social anxiety disorder. Topline results for PALISADE-1 anticipated mid-2022. PALISADE-2 on track for topline readout in late 2022. Received FDA consensus that data from nonclinical and clinical studies of PH94B completed to date provide no signal of abuse potential.

For further details see:

VistaGen Therapeutics GAAP EPS of -$0.25 misses by $0.03, revenue of $1.11M misses by $0.21M